The estimated Net Worth of Paul D Rubin is at least $1.25 million dollars as of 18 March 2016. Paul Rubin owns over 24,194 units of Cortexyme Inc stock worth over $636,872 and over the last 20 years Paul sold CRTX stock worth over $617,838.
Paul has made over 44 trades of the Cortexyme Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Paul sold 24,194 units of CRTX stock worth $18,871 on 18 March 2016.
The largest trade Paul's ever made was exercising 72,933 units of Cortexyme Inc stock on 22 March 2006 worth over $27,715. On average, Paul trades about 7,385 units every 59 days since 2004. As of 18 March 2016 Paul still owns at least 326,601 units of Cortexyme Inc stock.
You can see the complete history of Paul Rubin stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is C/O CRITICAL THERAPEUTICS, INC., 60 WESTVIEW STREET, LEXINGTON, MA, 02421.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi et Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: